AETERNUSPERFORMANCEJoin

Ipamorelin

Ipamorelin is a ghrelin-receptor growth hormone secretagogue discussed around GH-release research, endocrine selectivity, and safety limits.

Evidence level
Early human data
Human studies
2
Total sources
5
Last reviewed
2026-06-03

Reviewed by Bryan Powell · editorial review, not medical review

ghrelin receptor · GH secretagogue signaling · endocrine selectivity

At a glance

Ipamorelin is a growth hormone secretagogue topic, but it should not be framed like a general recovery or body-composition solution. The best evidence-aware profile explains its ghrelin-receptor pathway, the original selectivity claims, human PK/PD research, and the limits of translating GH-release data into practical outcomes.

What Ipamorelin is

Ipamorelin is a synthetic pentapeptide developed as a growth hormone secretagogue. Unlike GHRH analogs such as sermorelin or CJC variants, ipamorelin is discussed through the ghrelin or growth-hormone-secretagogue receptor pathway. That distinction matters because GHRH and ghrelin-receptor agonists are different endocrine signals, even when public conversations group them together.

Mechanism

Why It Shows Up in Growth Hormone Secretagogue Discussions

The biological context centers on ghrelin-receptor signaling, pituitary GH release, endocrine selectivity, and the broader growth hormone secretagogue class. Selectivity is a source-supported concept in the original pharmacology literature, but it should not be inflated into a broad safety promise. Receptor selectivity is not the same as predictable outcome or long-term risk certainty.

Ghrelin-Receptor Biology, Without Overstating It

Ipamorelin is discussed mechanistically as a GHRP-like receptor agonist that stimulates GH release. The original European Journal of Endocrinology paper supports the selectivity discussion, including comparison with earlier secretagogues and endocrine profiling. That evidence is useful for explaining why ipamorelin is distinct from older GHRPs.

Human volunteer PK/PD modeling supports the idea that ipamorelin can be studied through concentration-response relationships and GH-release dynamics. That kind of human pharmacology is meaningful, but it remains a narrow endpoint. A GH-release signal does not establish improved recovery, fat loss, sleep, connective-tissue outcomes, or cognitive performance.

What the evidence actually shows

Human data

Direct human trial evidence among the reviewed sources.

The reviewed sources include human volunteer PK/PD research and an investigational clinical-trial context outside performance use. This supports limited human evidence for pharmacology and trial-specific endpoints, not broad health, recovery, body-composition, or performance claims.

Preclinical data

Animal or in-vitro work. Does not establish human effect.

The original pharmacology includes in vitro and animal work supporting GH-release potency, receptor-pathway discussion, and selectivity context. Those models are useful for mechanism, but they do not establish practical human outcomes or long-term safety.

Anecdotal discussion

Reported experience. Not evidence of effect.

Anecdotal discussion around ipamorelin often focuses on being gentler, cleaner, or more selective than older secretagogues. Those phrases can become misleading if they are not tied to source-supported endocrine markers. Anecdote does not establish safety, product quality, response patterns, or clinical value.

Where people overreach

Selectivity is not a safety guarantee. Lower off-target endocrine signals in selected studies do not prove broad long-term safety.

GH release is not a practical outcome. A hormone-response endpoint should not be translated into assured recovery, sleep, physique, or aging effects.

Clinical context is limited. Human evidence exists, but it is narrow and does not validate wellness or performance use.

Product quality remains a separate issue. Published pharmacology does not establish the identity or safety of real-world products.

Safety and regulatory context

Regulatory status matters. FDA compounding-risk context for ipamorelin supports caution around immunogenicity, aggregation, peptide impurities, and limited safety information.

Endocrine context matters. GH secretagogue signaling should not be framed as a casual optimization strategy.

Outcome language should stay restrained. Selective GH release does not prove body-composition, recovery, sleep, or anti-aging benefits.

Practical interpretation

Ipamorelin appears in performance discussions because growth hormone secretagogues are often marketed around recovery, body composition, sleep, and aging. That public narrative moves faster than the evidence. Aeternus keeps the topic grounded in receptor biology, human PK/PD context, and uncertainty.

The practical interpretation should be conservative. Ipamorelin can be used as an educational example of how ghrelin-receptor signaling differs from GHRH analog signaling. It should not be converted into stack language, recovery promises, or personal endocrine advice.

What Ipamorelin is not

Not a GHRH analog. Ipamorelin works through growth hormone secretagogue receptor biology, not the same pathway as CJC or sermorelin.

Not a guaranteed recovery or physique outcome. GH-release data does not prove practical results.

Not a risk-free selective peptide. Selectivity claims need context and do not remove safety uncertainty.

Aeternus position

Aeternus views ipamorelin as a legitimate endocrine pharmacology topic with more nuance than public marketing usually allows. The evidence supports discussion of ghrelin-receptor signaling, GH-release dynamics, and selectivity boundaries. It does not support turning the compound into a recovery, physique, sleep, or anti-aging promise.

Regulatory status

Three separate questions, kept separate on purpose. Whether Ipamorelin appears on FDA’s pharmacy-compounding list, whether an approved medicine containing it exists, and whether it is banned in sport are three different things, and the answer to one tells you nothing about the others.

FDA 503A bulk substances list

On neither list

Does not appear on FDA’s Category 1 or Category 2 bulk substances lists.

Left FDA Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns. Those concerns remain published. FDA lists it as 'Ipamorelin acetate'. One nuance that is easy to miss: the 503A nomination was withdrawn, but it remains in Category 2 under section 503B, which governs outsourcing facilities. Added there 2023-09-29.

Primary source

Source directness: high — a named primary document states this outright

FDA approval

No FDA-approved product

Primary source

Source directness: high — a named primary document states this outright

WADA prohibited list

Prohibited at all times · S2.2.4 · named explicitly

Named among growth hormone secretagogues.

Primary source

Source directness: high — a named primary document states this outright

Verified against primary sources on 2026-07-31 · last regulatory change 2026-04-22

Regulatory status changes, sometimes quickly. This reflects what the primary sources said on the date above and nothing more. Verify before acting on it.

Sources (5)

  1. preclinical · moderateIpamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology, 1998 · doi:10.1530/eje.0.1390552
  2. human study · moderatePharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersPharmaceutical Research, 1999 · doi:10.1023/a:1018955126402
  3. human study · limitedProspective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsInternational Journal of Colorectal Disease, 2014 · doi:10.1007/s00384-014-2030-8
  4. review · moderateThe Safety and Efficacy of Growth Hormone SecretagoguesSexual Medicine Reviews, 2018 · doi:10.1016/j.sxmr.2017.02.004
  5. regulatory · moderateCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA, 2026

Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.

Other compounds in Hormone & Growth Signaling